61 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 29430 | Have a confirmed diagnosis of MF ; Require therapy for MF in the opinion of the Investigator and are eligible for treatment with ruxolitinib ; Have DIPSS risk category Intermediate-1 or higher | Néoplasme myéloprolifératif (MPN) | Constellation | Manifest-2 | Trial closed | A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients (Manifest-2) | 3 | 3 | |||
| 26201 | 1st line/ >= 60 years old and ineligible for autologous transplant/ Ann Arbor stage II-IV | Marie Maerevoet | Non-Hodgkin lymphoma | Lysarc | MCL-R2 Elderly | Trial closed for recruitment | Efficacy of alternating immunochemotherapy consisting of R-CHOP + R-HAD versus R-CHOP alone, followed by maintenance therapy consisting of additional lenalidomide with rituximab versus rituximab alone for older patients with mantle cell lymphoma | marie.maerevoet@hubruxelles.be | 3 | 3 | |
| 22979 | - relapsed or refractory follicular NHL grade 1-2-3a - has received at least 1 prior line of therapy - at least 1 lymph node of at least 1.5cm or 1 ectra nodal lesion > 1cm - QTcF < 450 msec |
Marie Maerevoet | Multiple | MEI Pharma | ME-401-003 (TIDAL) | Trial closed | A Multicenter, Open-Label, Single-Arm, Phase 2 Study of ME-401 in Subjects with Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies | marie.maerevoet@hubruxelles.be | 2 | 2 | |
| 29427 | Newly diagnosed subjects eligible for high dose therapy and autologous stem cell transplantation | Nathalie Meuleman | Myeloma | IFM | MIDAS | Trial closed for recruitment | MInimal residual Disease Adapted Strategy: frontline therapy for patients eligible for autologous stem cell transplantation less than 66 years; a prospective study from the French cooperative group (IFM) (MIDAS ; IFM2020-02) | nathalie.meuleman@hubruxelles.be | 3 | 3 | |
| 22667 | First relapse or progression Agressive NHL Age > 65 YO or >18 yo and HCT-CI score > 2 or prior ASCT and not eligible for allogeneic transplantation |
Marie Maerevoet | Non-Hodgkin lymphoma | LYSA LYmphoma | NIVEAU - DSHNHL 2015-01 | Trial closed | Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabine, Oxaliplatin plus Rituximab in case of B-cell lymphoma | marie.maerevoet@hubruxelles.be | 2/3 | 2 | |
| 22980 | Prospective MGUS patients: IgG, IgA or light chain MGUS, as defined by the International Myeloma Working Group (IMWG) Updated Criteria for the Diagnosis of Multiple Myeloma ? Prospective SMM patients: IgG, IgA or light chain SMM, as defined by the IMWG Up |
Nathalie Meuleman | Myeloma | Janssen | NOPRODMMY0001 | Trial open for recruitment | Myeloma Progression Omics Profling (MPOP) : An Atlas of High-Content Single-Cell Immunophenotyping and Single Cell Transcriptomics in Myeloma and its Precursor States | nathalie.meuleman@hubruxelles.be | |||
| 26122 | -DLBCL CD20 +de novo or transformed from low grade NHL or follicular lymphoma grade 3b -relapsed or refractory : Patients eligible for ASCT who failed to achieve a CR after at least one salvage therapy Or patients in first relapse after ASCT Or patients |
Marie Maerevoet | Multiple | LYSA LYmphoma | PIVeR | Trial closed | A multicentre, phase II, open label, single arm study of pixantrone in patients with CD20-positive relapsed or refractory aggressive non-Hodgkin lymphoma treated with rituximab, ifosfamide and etoposide (PIVeR) | marie.maerevoet@hubruxelles.be | 2 | 2 | |
| 22678 | Previously untreated patients with CD20-positive DLBCL - IPI score of 2-5 | Marie Maerevoet | Non-Hodgkin lymphoma | Lysarc | POLARIX | Trial closed for recruitment | POLARIX - GO39942 - A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma | marie.maerevoet@hubruxelles.be | 3 | 3 | |
| 26202 | histologically proven peripheral T-cell lymphoma (PTCL) | Dominique Bron | Lymphoma | Ro-CHOP | Trial closed | RoCHOP Phase 3 multi-center randomized study to compare efficacy and safety of Romidepsin-CHOP (Ro-CHOP) versus CHOP in subjects with previously untreated peripheral T-Cell Lymphoma | dominique.bron@hubruxelles.be | 3 | 3 | ||
| 22746 | At least 2 but no more than 5 previous systemic regimens - For patients whose most recent systemic anti-DLBCL therapy induced a PR or CR, at least 60 days must have elapsed since the end of that therapy | Marie Maerevoet | Non-Hodgkin lymphoma | Karyopharm | SADAL | Trial closed for recruitment | SADAL - A Phase 2b Open-label study of Selinexor (KPT-330) in Patients with Relapsed/ Refractory Diffuse Large B-Cell Lymphoma (DLBCL) |
marie.maerevoet@hubruxelles.be | 2 | 2 | |
| 22770 | Eligible to receive R-GDP - with at least one but no more than two lines therapies - no previous treatment with Selinexor | Marie Maerevoet | Non-Hodgkin lymphoma | Lysarc | SELINDA | Trial closed | A Phase IB study of oral selinexor in adult patients with relapsed/refractory B-cell lymphoma receiving R-DHAOx or R-GDP | marie.maerevoet@hubruxelles.be | 2 | 2 | |
| 22848 | Smoker of quit smoking within the last 6 months, any tumors | Solid tumors | Institut Jules Bordet | Sevrage Tabagique | Trial open for recruitment | Impact of an emotion and craving regulation intervention on smoking cessation and maintenance among oncology patients : a randomized study | |||||
| 22642 | HSCT, refractory or resistant CMV reactivation | Multiple | Shire | SOLSTICE | Trial closed | A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients with Cytomegalovirus (CMV) Infections that are Refractory or Resistant to Treatment with Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir | 3 | 3 | |||
| 29421 | RARA-positive, Newly diagnosed with HR-MDS, bone marrow blasts > 5%, adequate organ function | Chloé Spilleboudt | Syndromes myélodysplasiques (MSD) | SYROS Pharmaceuticals, Inc | SY-1425-301 | Trial open for recruitment | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of SY-1425 Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, RARA-positive Adult Patients with Higher-risk Myelodysplastic Syndrome | chloe.spilleboudt@hubruxelles.be | 3 | 3 |